Der Urologe

, 50:1283 | Cite as

Sekundär- und Tertiärprävention urologischer Tumore

  • B.J. Schmitz-Dräger
  • G. Lümmen
  • E. Bismarck
  • C. Fischer
  • die Mitglieder des Arbeitskreises Prävention, Umwelt und Komplementärmedizin (PUK)
Leitthema

Zusammenfassung

Datenlage und -qualität zum Thema der Sekundär-/Tertiärprävention urologischer Tumore sind weitgehend unbefriedigend. Im Bereich von Ernährung und Nahrungsergänzung könnte der Verzehr von Tomaten und insbesondere von Tomatenprodukten einen günstigen Effekt auf den Krankheitsverlauf von Patienten mit einem Prostatakarzinom haben, während es andererseits Hinweise darauf gibt, dass der Verzehr von Kalzium- (Milch/Milchprodukte) und α-Linolensäure-haltigen Nahrungsmitteln ebenso wie der Konsum einer fettreichen Ernährung die Tumorprogression beschleunigt. Trotz bislang noch unbefriedigender Datenlage sollten Männer mit Urotheltumoren oder einem Prostatakarzinom das Rauchen aufgeben und sich sportlich betätigen. Bei medikamentösen Maßnahmen stehen die Einnahme von 5α-Reduktasehemmern und die Gabe von knochenaktiven Substanzen bei Patienten mit einem Prostatakarzinom zur Diskussion. Die Wirksamkeit der Substanzen Zoledronat und Denosumab ist in prospektiv randomisierten Studien gut belegt. Die Autoren empfehlen, den bislang wissenschaftlich eher vernachlässigten Bereich der Tertiärprävention urologischer Tumore künftig in das Zentrum wissenschaftlicher Untersuchungen zu rücken.

Schlüsselwörter

Uroonkologie Prävention Vitamine Ernährung Supportion 

Secondary and tertiary prevention of urological tumors

Abstract

The amount and quality of available data on secondary and tertiary prevention of urological tumors are to a large extent unsatisfactory. In the areas of nutrition and supplementary diet the consumption of tomatoes and especially tomato products could have a beneficial effect on the course of the disease for patients with prostate cancer, whereas there is evidence that the consumption of foodstuffs containing calcium (milk and milk products) and linolenic acid as well as a fat-rich diet accelerate tumor progression. Despite as yet unsatisfactory data, men with urothelial tumors or prostate cancer should abstain from smoking and undertake sports activities. For medicinal measures the administration of 5-alpha-reductase inhibitors and bone-promoting substances for patients with prostate cancer are under discussion. The effectiveness of the substances zoledronate and denosumab has been demonstrated in prospective randomized studies. The authors recommend that the scientifically neglected field of tertiary prevention of urological tumors should in future be included as a core factor of scientific investigations.

Keywords

Urooncology Prevention Vitamins Nutrition Supportive therapy 

Notes

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Marshall JR, Sakr W, Wood D et al (2006) Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 15(8):1479–1484PubMedCrossRefGoogle Scholar
  2. 2.
    Marshall JR, Sakr W, Wood D et al (2011) 108th Annual Meeting. American Urological Association, San Francisco (Mai 14–19, 2011)Google Scholar
  3. 3.
    Giovannucci E, Liu Y, Platz EA et al (2007) Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 121(7):1571–1578PubMedCrossRefGoogle Scholar
  4. 4.
    Park Y, Mitrou PN, Kipnis V et al (2007) Calcium, dairy foods, and risk of incident and fatal prostate cancer: the NIH-AARP Diet and Health Study. Am J Epidemiol 166:1270–1279PubMedCrossRefGoogle Scholar
  5. 5.
    Meyer F, Bairati I, Shadmani R et al (1999) Dietary fat and prostate cancer survival. Cancer Causes Control 10(4):245–251PubMedCrossRefGoogle Scholar
  6. 6.
    Weerden WM van, Schröder FH (2008) The use of PSA as biomarker in nutritional intervention studies of prostate cancer. Chem Biol Interact 171(2):204–211PubMedCrossRefGoogle Scholar
  7. 7.
    Newton RU, Galvão DA (2008) Exercise in prevention and management of cancer. Curr Treat Options Oncol 9(2–3):135–146Google Scholar
  8. 8.
    Culos-Reed SN, Robinson JW, Lau H et al (2010) Physical activity for men receiving androgen deprivation therapy for prostate cancer: benefits from a 16-week intervention. Support Care Cancer 18(5):591–599PubMedCrossRefGoogle Scholar
  9. 9.
    Aveyard P, Adab P, Cheng KK et al (2002) Does smoking status influence the prognosis of bladder cancer? A systematic review. BJU Int 90:228–239PubMedCrossRefGoogle Scholar
  10. 10.
    Lammers RJM, Witjes WPJ, Hendricksen K et al (2011) Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer. Eur Urol, doi:10.1016/j.eururo.2011.07.010 (in press)Google Scholar
  11. 11.
    Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E (2011) Smoking and prostate cancer survival and recurrence. JAMA 305:2548–2555PubMedCrossRefGoogle Scholar
  12. 12.
    Thompson IM, Goodman PJ, Tangen CM et al (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224PubMedCrossRefGoogle Scholar
  13. 13.
    Schmitz-Dräger BJ, Lümmen G, Bismarck E et al (2011) Primärprävention urologischer Tumore: Prostatakarzinom. Urology (in Druck)Google Scholar
  14. 14.
    Thompson IM, Lucia MS, Redman MW et al (2007) Finasteride decreases the risk of prostatic intraepithelial neoplasia. J Urol 178(1):107–109PubMedCrossRefGoogle Scholar
  15. 15.
    Finelli A, Trottier G, Lawrentschuk N et al (2011) 5-Alpha reductase inhibitors diminish the rate of progression in men with low risk prostate cancer on active surveillance. 109th Annual Meeting, American Urological Association, Washington (Mai 14–19, 2011)Google Scholar
  16. 16.
    Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468PubMedGoogle Scholar
  17. 17.
    Heidenreich A, Aus G, Bolla M et al (2008) European Association of Urology. EAU guidelines on prostate cancer. Eur Urol 53:68–80PubMedCrossRefGoogle Scholar
  18. 18.
    Wirth M, Weißbach L, Ackermann R et al (Hrsg) (2009) Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. DGU, DüsseldorfGoogle Scholar
  19. 19.
    Heidenreich A, Elert A, Hofmann R (2002) Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 5:231–235PubMedCrossRefGoogle Scholar
  20. 20.
    Smith MR, Eastham J, Gleason DM et al (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169:2008–2012PubMedCrossRefGoogle Scholar
  21. 21.
    Michaelson MD, Kaufman DS, Lee H et al (2007) Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 25:1038–1042PubMedCrossRefGoogle Scholar
  22. 22.
    Wadhwa VK, Weston R, Parr NJ (2010) Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer. BJU Int 105:1082–1088CrossRefGoogle Scholar
  23. 23.
    Campbell SC, Bhoopalam N, Moritz TE et al (2010) The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis. Urology 75:1138–1143PubMedCrossRefGoogle Scholar
  24. 24.
    Yuen KK, Shelley M, Sze WM et al (2006) Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev 18(4):CD006250Google Scholar
  25. 25.
    Saad F, Gleason DM, Murray R et al (2004) Longterm efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882PubMedCrossRefGoogle Scholar
  26. 26.
    Saad F, Chen YM, Gleason DM, Chin J (2007) Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer 5:390–396PubMedCrossRefGoogle Scholar
  27. 27.
    Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768):813–822PubMedCrossRefGoogle Scholar
  28. 28.
    Miller K, Fizazi K, Smith M et al (2011) Benefit of Denosumab therapy in patients with bone metastases from castrate resistant prostate cancer: a number-needed-to-treat (nnt) analysis. 109th Annual Meeting. American Urological Association, Washington (Mai 14–19, 2011)Google Scholar
  29. 29.
    Smith MR, Saad F, Coleman R et al (2011) Denosumab to prolong bone metastasis-free survival in men with castrate resistent prostate cancer: results of a global phase III, randomized, double-blind trial. 109th Annual Meeting. American Urological Association, Washington (Mai 14–19, 2011)Google Scholar
  30. 30.
    Aapro MS (2007) Management of bisphosphonate treatment in clinical practice. Semin Oncol 34(6 Suppl 4):28–32CrossRefGoogle Scholar
  31. 31.
    Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev (3):CD003474Google Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • B.J. Schmitz-Dräger
    • 1
  • G. Lümmen
    • 2
  • E. Bismarck
    • 1
  • C. Fischer
    • 3
  • die Mitglieder des Arbeitskreises Prävention, Umwelt und Komplementärmedizin (PUK)
  1. 1.UrologieEuromedClinicFürthDeutschland
  2. 2.Klinik für UrologieSt. Josef-Hospital TroisdorfTroisdorfDeutschland
  3. 3.Urologische KlinikKlinikum Hohe WarteBayreuthDeutschland

Personalised recommendations